首页|Formin-Like 2 Is a Potential Biomarker of Poor Prognosis in Nasopharyngeal Carcinoma

Formin-Like 2 Is a Potential Biomarker of Poor Prognosis in Nasopharyngeal Carcinoma

扫码查看
原文链接
  • NSTL
  • Karger
Introduction: Nasopharyngeal carcinoma (NPC) is the most common malignant tumor in southern China and Southeast Asia. Although substantial research on NPC has been conducted, the resulting improvement in clinical outcomes remains very disappointing. NPC treatment typically involves radiation therapy and chemotherapy, but the high incidence of metastasis and recurrence in NPC patients result in poor survival. Therefore, identifying potential biomarkers and discovering therapeutic targets are necessary to design tailored treatments based on the genetic profiles of NPC patients. Methods: Correlations of protein immunostaining with clinicopathological features were analyzed by Pearson’s χ 2 test. The Kaplan-Meier method with a log-rank test was used to generate survival curves. Multivariate analysis was performed using the Cox proportional hazards model. Results: In this study, we comparatively analyzed cytoskeletal organization and biogenesis (GO:0007010) and tumorigenesis in the NPC transcriptome (GSE12452) and found that formin-like 2 (FMNL2) expression was significantly upregulated in NPC tumor tissues. Moreover, high FMNL2 expression was significantly correlated with primary tumor stage (p = 0.001), lymph node status (p = 0.004), cancer stage (p = 0.006), and histological grade (p = 0.040). More importantly, high FMNL2 expression was significantly correlated with poor survival in NPC patients according to univariate analysis and multivariate analysis. Conclusion: This study reveals that FMNL2 may be an important potential biomarker for evaluating the prognosis of NPC patients.

Nasopharyngeal carcinomaCytoskeleton organizationFormin-like 2Prognostic marker

Cheng-Fa,Yeh、Yu-Hsuan,Kuo、Nai-Wen,Kang、Tzu-Ju,Chen、Shih-Lun,Chang、Sung-Wei,Lee、Ching-Chieh,Yang、Hong-Yue,Lai、Hsin-Hwa,Tsai

展开 >

Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan

Division of Hematology and Oncology, Department of Internal Medicine, Chi-Mei Medical Center

Institute of Biomedical Science, National Sun Yat-Sen University, Kaohsiung, Taiwan

Department of Otolaryngology, Chi Mei Medical Center, Tainan, Taiwan

Department of Radiation Oncology, Chi Mei Medical Center, Liouying, Taiwan

Department of Radiation Oncology, Chi Mei Medical Center, Tainan, Taiwan

Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan

展开 >

2022

10.1159/000525682

Oncology

Oncology

SCI
ISSN：0030-2414
年,卷(期)：2022.100(9)
  • 30